JP2009528346A - Ｒｐｓ２７ｌタンパク質をコードする核酸の活性を調節することによる癌治療に対する細胞の感作 - Google Patents

Ｒｐｓ２７ｌタンパク質をコードする核酸の活性を調節することによる癌治療に対する細胞の感作 Download PDF

Info

Publication number
JP2009528346A
JP2009528346A JP2008557241A JP2008557241A JP2009528346A JP 2009528346 A JP2009528346 A JP 2009528346A JP 2008557241 A JP2008557241 A JP 2008557241A JP 2008557241 A JP2008557241 A JP 2008557241A JP 2009528346 A JP2009528346 A JP 2009528346A
Authority
JP
Japan
Prior art keywords
rps27l
cells
cell
nucleic acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528346A5 (https=
Inventor
ユイ、チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2009528346A publication Critical patent/JP2009528346A/ja
Publication of JP2009528346A5 publication Critical patent/JP2009528346A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008557241A 2006-03-02 2007-03-01 Ｒｐｓ２７ｌタンパク質をコードする核酸の活性を調節することによる癌治療に対する細胞の感作 Pending JP2009528346A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77851906P 2006-03-02 2006-03-02
PCT/SG2007/000058 WO2007100305A1 (en) 2006-03-02 2007-03-01 Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding rps27l protein

Publications (2)

Publication Number Publication Date
JP2009528346A true JP2009528346A (ja) 2009-08-06
JP2009528346A5 JP2009528346A5 (https=) 2010-04-15

Family

ID=38459335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557241A Pending JP2009528346A (ja) 2006-03-02 2007-03-01 Ｒｐｓ２７ｌタンパク質をコードする核酸の活性を調節することによる癌治療に対する細胞の感作

Country Status (6)

Country Link
US (1) US20090137517A1 (https=)
EP (1) EP1996206A4 (https=)
JP (1) JP2009528346A (https=)
AU (1) AU2007221503A1 (https=)
TW (1) TW200800236A (https=)
WO (1) WO2007100305A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513520A (ja) * 2010-12-29 2014-06-05 シグマ−アルドリッチ・カンパニー、エルエルシー Ａｄｍｅおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞
WO2018124118A1 (ja) * 2016-12-27 2018-07-05 住友化学株式会社 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010792B1 (en) 2006-04-26 2015-03-25 Litens Automotive Partnership One-way isolator for high torque devices
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119260A2 (en) * 2004-06-03 2005-12-15 Bayer Healthcare Ag Methods for predicting and monitoring response to cancer therapy
WO2006006939A1 (en) * 2004-07-09 2006-01-19 Agency For Science, Technology And Research MODULATION OF GSK-3β AND METHOD OF TREATING PROLIFERATIVE DISORDERS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119260A2 (en) * 2004-06-03 2005-12-15 Bayer Healthcare Ag Methods for predicting and monitoring response to cancer therapy
WO2006006939A1 (en) * 2004-07-09 2006-01-19 Agency For Science, Technology And Research MODULATION OF GSK-3β AND METHOD OF TREATING PROLIFERATIVE DISORDERS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012021827; Ｃｅｌｌ ｖｏｌ．１２４, 2006, ｐ．２０７-２１９ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513520A (ja) * 2010-12-29 2014-06-05 シグマ−アルドリッチ・カンパニー、エルエルシー Ａｄｍｅおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞
JP2017029138A (ja) * 2010-12-29 2017-02-09 シグマ−アルドリッチ・カンパニー、エルエルシー Ａｄｍｅおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞
WO2018124118A1 (ja) * 2016-12-27 2018-07-05 住友化学株式会社 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法
JPWO2018124118A1 (ja) * 2016-12-27 2019-10-31 住友化学株式会社 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法
JP7141043B2 (ja) 2016-12-27 2022-09-22 住友化学株式会社 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法

Also Published As

Publication number Publication date
EP1996206A1 (en) 2008-12-03
TW200800236A (en) 2008-01-01
AU2007221503A1 (en) 2007-09-07
WO2007100305A1 (en) 2007-09-07
US20090137517A1 (en) 2009-05-28
EP1996206A4 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
JP2009528346A (ja) Ｒｐｓ２７ｌタンパク質をコードする核酸の活性を調節することによる癌治療に対する細胞の感作
JP7392954B2 (ja) トリプルネガティブ乳癌の治療方法
WO2016065349A2 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
JP2014028853A (ja) 癌治療と幹細胞調節のための方法
US20160187319A1 (en) Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
Blumental-Perry et al. Retrograde signaling by a mtDNA-encoded non-coding RNA preserves mitochondrial bioenergetics
US20120087992A1 (en) miRNAS AS THERAPEUTIC TARGETS IN CANCER
CN104302767A (zh) 用于减少肺癌肿瘤发生和化学疗法抗性的MiRNA以及相关组合物和方法
CN104619353A (zh) 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
JP5341081B2 (ja) 肝細胞癌処置用医薬組成物および医薬キット
JP2016196486A (ja) 脳腫瘍を治療するための分枝鎖アミノトランスフェラーゼ１（ｂｃａｔ１）の阻害剤
WO2013113032A1 (en) G protein-coupled purinergic receptor gpr17 mediates orexigenic effects of foxo1 in agrp neurons
Ferreira et al. The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies
JP2023520440A (ja) 構造標的化リガンドによる発がん性マイクロｒｎａ１７－９２クラスターの標的分解
US20240125768A1 (en) Methods for modulating a src-1 condensate
US20230270881A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
WO2013122321A1 (ko) Ｈｄａｃ６의 간암 진단용 마커 및 치료제로서의 용도
KR20230019774A (ko) Gas5 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
KR102143701B1 (ko) nc886 및/또는 PKR 저해제를 포함하는 항암 보조제, 및 암 치료를 위한 약물의 정보 제공 방법
US20120252737A1 (en) Methods for Diagnosing and Treating Cancer
ES2637032B1 (es) Composición para promover la recuperación cardiaca tras un infarto de miocardio (IM)
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
KR102270926B1 (ko) Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물
WO2008069621A1 (en) Novel use of mig12 and oip5 genes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100225

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115